Background: Recent studies have demonstrated the activation of coagulation pathways in asthmatic airways. This study aimed to determine systemic blood coagulation during asthma exacerbation compared with the stable state in children. Methods: Pediatric patients (aged between 5 and 15 years) suffering from asthma exacerbation were enrolled. von Willebrand factor (vWF), plasminogen activator inhibitor type-1 (PAI-1), protein C, D-dimer, prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), and C-reactive protein (CRP) levels were measured during asthma exacerbation and stable state. Results: A total of 22 patients were enrolled. The median vWF, PAI-1, and CRP during asthma exacerbation were significantly higher than those of the stable state: 147.5% (interquartile range, IQR: 111.05-196.57) versus 94% (IQR: 69.72-109.62, p < 0.001), 41.9 ng/ml (IQR: 21.91-48.61) versus 26.17 ng/ml (IQR: 15.89-34.44, p < 0.03), and 4.46 mg/l (IQR: 2.15-16.23) versus 0.87 mg/l (IQR: 0.20-3.89, p < 0.015), respectively. However, the median protein C during asthma exacerbation was significantly lower than that of the stable state: 99.5% (IQR: 86.75-117) versus 113% (IQR: 94-115.25), p = 0.01. No significant difference was found between the levels of D-dimer, F1 + 2, and TAT during asthma exacerbation and stable state. Ultimately, D-dimer was positively correlated with asthma exacerbation score (R = 0.466, p = 0.027). A significant correlation was observed between vWF and CRP (R = 0.527, p = 0.012). Conclusion: Evidence was found of increased endothelial activation and increased PAI-1 during asthma exacerbation. This may emphasize the potential role of blood coagulation in asthma exacerbation.

1.
Manuyakorn W, Howarth PH, Holgate ST: Airway remodelling in asthma and novel therapy. Asian Pac J Allergy Immunol 2013;31:3-10.
2.
Schouten M, Van De Pol MA, Levi M, Van Der Poll T, Van Der Zee JS: Early activation of coagulation after allergen challenge in patients with allergic asthma. J Thromb Haemost 2009;7:1592-1594.
3.
Kemona-Chetnik I, Kowal K, Kucharewicz I, Pampuch A, Bodzenta-Lukaszyk A: Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients (in Polish). Przegl Lek 2006;63:1281-1285.
4.
Kemona-Chetnik I, Bodzenta-Lukaszyk A, Kucharewicz I, Rogalewska AM: Tissue factor and tissue factor pathway inhibitor during specific bronchial challenge in allergic asthma patients (in Polish). Przegl Lek 2005;62:98-101.
5.
Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H, Yamaguchi M, Jinnai M, Muro S, Hirai T, Ito Y, Nakamura T, Mio T, Chin K, Mishima M: High-sensitivity C-reactive protein in asthma. Eur Respir J 2006;27:908-912.
6.
Fujita M, Ueki S, Ito W, Chiba T, Takeda M, Saito N, Kayaba H, Chihara J: C-reactive protein levels in the serum of asthmatic patients. Ann Allergy Asthma Immunol 2007;99:48-53.
7.
Razi E, Ehteram H, Akbari H, Chavoshi V, Razi A: Evaluation of high-sensitivity C-reactive protein in acute asthma. Tanaffos 2012;11:32-37.
8.
Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Mroczko B, Szmitkowski M, Bodzenta-Lukaszyk A: Changes in high-sensitivity C-reactive protein in serum and exhaled breath condensate after intensive exercise in patients with allergic asthma. Int Arch Allergy Immunol 2010;153:75-85.
9.
Levi M, van der Poll T: Inflammation and coagulation. Crit Care Med 2010;38:S26-S34.
10.
Chuansumrit A, Chaiyaratana W: Hemostatic derangement in dengue hemorrhagic fever. Thromb Res 2014;133:10-16.
11.
van Wissen M, Keller TT, van Gorp EC, Gerdes VE, Meijers JC, van Doornum GJ, Büller HR, Brandjes DP: Acute respiratory tract infection leads to procoagulant changes in human subjects. J Thromb Haemost 2011;9:1432-1434.
12.
Preutthipan A: Status asthmaticus; in Khositseth A, Limrungsikul A (eds): Pediatrics Critical Care. Bangkok, Deewan, 2013, pp 495-510.
13.
The Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. http://www.ginasthma.org/.
14.
Pintadit P, Chuansumrit A, Chotsupakarn S, Krasaesub S, Panthankul W, Isarangkura P: Carrier detection in hemophilia A by using the ratio of factor VIII clotting activity and von Willebrand factor antigen. Thai J Hematol Transf Med 1996;6:24-31.
15.
Levi M, Schultz MJ, Rijneveld AW, van der Poll T: Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003;31:S238-S242.
16.
Aird WC: Phenotypic heterogeneity of the endothelium. I. Structure, function, and mechanisms. Circ Res 2007;100:158-173.
17.
Page AV, Liles WC: Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence 2013;4:507-516.
18.
Neyrinck AP, Liu KD, Howard JP, Matthay MA: Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol 2009;158:1034-1047.
19.
Majoor CJ, van de Pol MA, Kamphuisen PW, Meijers JC, Molenkamp R, Wolthers KC, van der Poll T, Nieuwland R, Johnston SL, Sterk PJ, Bel EH, Lutter R, van der Sluijs KF: Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respir Res 2014;15:14.
20.
Boyle JP, Smart RH, Shirey JK: Heparin in the treatment of chronic obstructive bronchopulmonary disease. Am J Cardiol 1964;14:25-28.
21.
Fine NL, Shim C, Williams MH Jr: Objective evaluation of heparin in the treatment of asthma. Am Rev Respir Dis 1968;98:886-887.
22.
Hataji O, Taguchi O, Gabazza EC, Yuda H, Fujimoto H, Suzuki K, Adachi Y: Activation of protein C pathway in the airways. Lung 2002;180:47-59.
23.
Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ: The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010;115:1121-1130.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.